贝达药业: 第四届监事会第二十一次会议决议公告

Group 1 - The company held a supervisory board meeting to discuss the first vesting period of the 2023 Restricted Stock Incentive Plan, confirming that the vesting conditions have been met for 2,897,827 shares for 479 eligible participants [1][2] - The supervisory board approved the cancellation of 2,262,482 shares of restricted stock that have not vested due to reasons such as employee resignation and performance assessment failures, ensuring compliance with relevant regulations [2][1] - The voting results for both proposals were unanimous, with 3 votes in favor and no votes against or abstentions, indicating strong support from the supervisory board [2]